CS
MNPR icon

Candriam SCA’s Monopar Therapeutics MNPR Stock Holding History

Candriam SCA’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.3M Buy
+143,339
New +$8.87M 0.06% 252

Other funds holding MNPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Candriam SCA's MNPR Position: Q2 2026 in Review

Candriam SCA opened a new position in Monopar Therapeutics (MNPR) in Q2 2026: 143,339 shares worth $13.3M. The stake represents 0.06% of the portfolio and ranks #252 among its holdings.

51 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

  • Candriam SCA held 143,339 shares of Monopar Therapeutics worth $13.3M as of Q2 2026.
  • Monopar Therapeutics was a new Candriam SCA position in Q2 2026.
  • Monopar Therapeutics made up 0.06% of Candriam SCA's portfolio in Q2 2026, its #252 holding.
  • 51 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.